A molecule thought to be a natural antioxidant, pterostilbene (PTE) prevented signs of idiopathic pulmonary fibrosis (IPF) from occurring…
Forest Ray PhD
Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Forest Ray PhD
Stem cells found in human umbilical cords limited lung damage associated with pulmonary fibrosis (PF) by reducing an excessive…
Idiopathic pulmonary fibrosis (IPF) co-occurring with a second lung disorder represents a distinct new IPF subtype with a poor…
A new, automated computer image analysis technique was able to accurately assess and measure the severity of pulmonary fibrosis…
NeRRe Therapeutics has raised £20 million (nearly $28 million) to develop orvepitant as a treatment for the chronic…
Alterations in the extracellular matrix — the network of molecules that surrounds and supports cells — and cell aging, a…
Gefapixant (MK-7264), an investigational cough suppressant, was safe and well-tolerated by patients with idiopathic pulmonary fibrosis (IPF), but did not…
Hyperbaric oxygen therapy can counteract some of the key features of pulmonary fibrosis (PF) in mice and human lung…
Investigators have discovered a new biomarker in a molecule called cutaneous T-cell-attracting chemokine, or CTACK, that may help determine the…
The acid reflux medication esopremazole, commonly used to ease symptoms of gastroesophageal reflux disease (GERD), may be able to…